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Abstract Fibrillar aSynuclein is the major constituent of
Lewy bodies and Lewy neurites, the protein deposits charac-
teristic for Parkinson’s disease (PD). Multiplications of the
aSynucleingene,aswellaspointmutationscausefamilialPD.
However, the exact role of aSynuclein in neurodegeneration
remains uncertain. Recent research in invertebrates has sug-
gested that oligomeric rather than ﬁbrillizing aSynuclein
mediates neurotoxicity. To investigate the impact of aSyn-
uclein aggregation on the progression of neurodegeneration,
we expressed variants with different ﬁbrillation propensities
in the rat substantia nigra (SN) by means of recombinant
adeno-associated viral (AAV) vectors. The formation of
proteinase K-resistant aSynuclein aggregates was correlated
to the loss of nigral dopaminergic (DA) neurons and striatal
ﬁbers. Expression of two preﬁbrillar, structure-based design
mutants of aSynuclein (i.e., A56P and A30P/A56P/A76P)
resulted in less aggregate formation in nigral DA neurons as
compared to human wild-type (WT) or the inherited A30P
mutation. However, only the aSynuclein variants capable of
formingﬁbrils(WT/A30P),butnottheoligomericaSynuclein
species induced a sustained progressive loss of adult nigral
DA neurons. These results demonstrate that divergent modes
of aSynuclein neurotoxicity exist in invertebrate and mam-
malian DA neurons in vivo and suggest that ﬁbrillation of
aSynuclein promotes the progressive degeneration of nigral
DA neurons as found in PD patients.
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Introduction
Parkinson’s disease (PD) is the most prevalent neurodegen-
erative movement disorder, affecting more than 2% of
individuals over the age of 60 years. Pathological hallmarks
of the disease are the progressive loss of dopaminergic (DA)
neurons in the substantia nigra pars compacta (SNpc) and the
presenceofproteinousaggregatestermedLewybodieswithin
DA neurons, which are predominantly composed of ﬁbrillar
aSynuclein [27]. Gene triplication and inherited mutations of
aSynucleincauseearly-onsetPD,demonstratingacrucialrole
for aSynuclein in the etiology of the disease [11, 17]. How-
ever, how aSynuclein induces neurodegeneration remains as
elusive as its physiological function.
aSynuclein belongs to the class of intrinsically disordered
proteins in solution, but it adopts a partially folded structure
upon a variety of environmental stimuli [41]. While mem-
brane bound a-helical aSynuclein does not contribute to
aggregation and ﬁbrillation [47], soluble folding intermedi-
atesarethoughttobeessentialfortheinitiationofaggregation
of the protein by a cascade comprising initially soluble, then
insoluble oligomers, and ﬁnally ﬁbrils as found in Lewy
bodies [13]. The predominant physiological species of
aSynuclein in cells and brain is a helically folded tetramer
with a low propensity to aggregate into ﬁbrils [3].
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DOI 10.1007/s00401-011-0926-8Lewy bodies are usually found in living neurons and are
also present in 10–15% of healthy, aged individuals [15,
18]. Considering Lewy bodies as a protective sink for
misfolded proteins rather than a toxic entity is therefore an
attractive, but controversially discussed hypothesis [20].
Given the strong indications that aSynuclein is causally
involved in degeneration of nigral DA neurons, it seems
likely that oligomeric aSynuclein rather than ﬁbrillar
aggregates are the mediators of neuronal death. Conse-
quently, the ‘‘toxic oligomer’’ hypothesis was postulated [6,
42, 46]. This hypothesis gained further support by a recent
study in several invertebrate and cell-culture model systems
of PD which reported increased neurotoxicity upon over-
expression of aSynuclein variants that exhibited increased
propensity to form oligomeric, preﬁbrillar structures and
decreased propensities to form ﬁbrillar aggregates [22].
Considering that species likeDrosophila and C.elegansdo
not express aSynuclein orthologs, assessing aggregate for-
mation and correlating aggregates to neurodegeneration to
evaluatetheirrelevanceforPDshouldideallybeperformedin
adult mammalian DA neurons. In addition, PD is a slowly
progressing disorder and a correlation of aSynuclein aggre-
gation with the progressive loss of nigral DA neurons has not
been assessed so far. To evaluate long-term effects of aSyn-
uclein aggregate formation on DA neuron survival, we
expressed aSynuclein variants with different aggregation
propensities in neurons oftherat SN andquantiﬁedtheloss of
DA neurons over a time course of 3.5 months. To interfere
with aggregation, the single-proline mutation found in the
familial A30P mutant was moved to a position within the b-
sheet rich core of aSynuclein ﬁbrils. The single-proline
aSynuclein mutant A56P as well as the triple-proline mutant
A30P/A56P/A76P (TP) showed drastically reduced propen-
sitytoformproteinaseK(PK)-resistantaggregatesinvitroand
invivo,conﬁrmingthepriorcharacterizationofthemutantsas
preﬁbrillaraSynucleinvariantsbybiophysicalmethodsandin
invertebrates[22].However,onlytheaSynucleinspecieswith
increased aggregation propensities, human wild-type (WT)
and A30P, triggered a further progressing degeneration of
nigral DA neurons, and WT aSynuclein showed the highest
degree ofneurotoxicity afterlonger term overexpression. Our
ﬁndings suggest that ﬁbril formation of aSynuclein promotes
theprogressivedegenerationofnigralDAneuronsasfoundin
PD patients and show that invertebrate and mammalian DA
neurons are differently vulnerable to aSynuclein aggregation.
Materials and methods
AAV-vector production
AAV2 serotype vectors were constructed to express the
human WT aSynuclein, the inherited A30P mutation, the
two pre-ﬁbrillary aSynuclein mutants A56P and A30P/
A56P/A76P (TP), and EGFP. AAV2 serotype vectors were
prepared essentially as previously described [38]. Their
genomes consisted of AAV2 ITRs, human synapsin-1 gene
promoter driving expression of aSynuclein variants,
WPRE for enhanced mRNA stability and bovine growth
hormone polyadenylation site. For Western blot assessing
expression levels, primary cortical neuronal cultures were
prepared from rat embryos at E18. Western blotting and
preparation of conditioned medium and cell extracts were
performed according to the procedure described previously
[26].
Stereotaxic injection and tissue processing
All surgical procedures, intracerebral stereotaxic vector
injections into the left hemisphere SNpc (coordinates were
AP: -5.3; ML: ?2.2; DV: -7.7 mm, relative to bregma)
and tissue preparations were performed as described [37].
Young adult female Wistar rats (250–280 g) were injected
with a total of 2 ll containing 1.2 9 10
8 transducing units.
Animals were sacriﬁced at 2, 4, 8 and 14 weeks after virus
injection. 30-lm thick serial coronal sections from both the
SN and striatum were collected on a cryostat (Leica) and
processed for immunohistochemistry.
Immunohistochemistry
The following primary antibodies against aSynuclein
were used: mouse anti-human LB509 and syn211 (1:500,
Invitrogen), 5C2 (1:500, Santa Cruz), and mouse
anti-aSynuclein (1:500, Clone 42, BD Transduction
Laboratories) recognizing human and rat aSynuclein.
Immunoﬂuorescent visualization of DA neurons was
performed with rabbit polyclonal antibody against tyro-
sine hydroxylase (TH, 1:1,000, AB152). Monoclonal
anti-b-Tubulin was obtained from Sigma. Primary anti-
bodies were applied for 48 h at 4C followed by 1 h
incubation at RT with secondary antibodies on free-
ﬂoating sections. For indirect immunoﬂuorescence and
Western-blot analysis, secondary antibodies against rab-
bit or mouse IgGs and conjugated with Cy2, Cy3, or
horseradish peroxidase were used (Dianova). For the
SNpc, every fourth section was used for immunohisto-
chemistry (-4.52 to -6.3 mm, relative to bregma). For
the striatum, one rostral and one caudal section were
processed for each condition. Bright-ﬁeld and ﬂuorescent
images were taken on an Axioplan microscope equipped
with a 16-bit greyscale CCD camera using AxioVision
4.6 software (Zeiss). Some sections were examined with
a laser-scanning confocal microscope (Leica TCS SP5)
or with an ApoTome (Zeiss).
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For the bright-ﬁeld microscopy analysis, visualization of
DA neurons was performed with rabbit polyclonal antibody
against vesicular monoamine transporter 2 (VMAT2,
AB1767, Chemicon). Sections were preincubated ﬁrst with
3% H2O2/10% methanol for 5 min and then with 5%
normal goat serum for 1 h before incubation with the pri-
mary antibody VMAT2 (1:3,000, 4C, 48 h). Incubation
with biotinylated secondary anti-rabbit antibody (1:250) at
room temperature for 1 h was followed by the avidin–
biotin complex (ABC, Vector laboratories) method. The
reaction product was visualized using 3,30-diaminobenzi-
dine tetrachloride (DAB, Sigma) as a chromogen.
To estimate the total number of DA neurons, VMAT2-
immunoreactive cells were counted by stereology in every
fourth brain section in the region of the SNpc (10 sections
throughout the SN). VMAT2-positive cells of the ventral
tegmental area were excluded from counting. Cell counts
were performed in a blind manner using the StereoInves-
tigator software (MicroBrightField, Bioscience). Unbiased
stereological estimates of the total number of VMAT2-
positive neurons per SNpc were obtained using the optical
fractionator method [43]. Survival of DA neurons was
analyzed at 2, 4, 8, and 14 weeks after vector administra-
tion, with exception of the EGFP group, which was
sacriﬁced at the last time point only.
PK digest
Insolubility of the human aSynuclein aggregates was
demonstrated utilizing a modiﬁed version of a PK diges-
tion and immunohistochemistry protocol [12]. Free-
ﬂoating sections collected from brains 2 and 4 weeks after
viral-vector injection were digested in PBS containing
10 lg/ml PK (Invitrogen) for a period of 10 min at 55C.
Longer incubation times with PK resulted in disintegration
of the tissue and were therefore avoided. Maximum incu-
bation time and temperature were established in
preliminary experiments. Control sections adjacent to the
digested ones were incubated in PBS only. Sections were
quenched with 3% H2O2/10% methanol for 8 min and
processed for immunohistochemistry using the syn211
antibody, that recognizes human aSynuclein protein.
Immunoreactivity was visualized with the Vector ABC
DAB system. All slices were processed simultaneously
under strictly the same conditions and image acquisition
and measurements were performed with the exact same
settings and parameters. Bright-ﬁeld images of the SN
were taken on an Axioplan microscope equipped with a
639 oil immersion objective and using AxioVision soft-
ware (Zeiss, Germany). Quantitative data were extracted
with the MacBiophotonics ImageJ program (NIH,
Maryland, USA, http://rsb.info.nih.gov/ij/). To estimate the
PK-resistant fraction of aSynuclein, we performed mea-
surements in at least six randomly selected ﬁelds per image
from at least six images each. Cell somata were excluded
from the quantiﬁcation of the neuropil. As transgene
expression was restricted to the injected side in all animals,
we used the uninfected contralateral hemisphere as well as
EGFP transduced sections to set the lower threshold value
to correct for non-speciﬁc background. The upper thresh-
old value was deﬁned in undigested control sections.
For Thioﬂavin-S (ThioS) staining, mounted sections
were incubated with 0.05% ThioS (Sigma) in 50% ethanol
for 8 min after a quenching procedure to reduce back-
ground autoﬂuorescence [39] and antibody incubations.
Sections were differentiated in two changes of 80% ethanol
for 10 s each, washed three times in large volumes of PBS,
incubated with DAPI for 5 min and washed again.
Statistical analysis
Multiple comparisons were made by one-way ANOVA
followed by Tukey’s honestly signiﬁcant difference test.
The unpaired t test with Welch correction was used for
statistical comparison between two groups. Differences
were considered signiﬁcant at p\0.05. Statistical tests
were performed using the R software package [36].
Results
Diminished aggregate formation by preﬁbrillar
aSynuclein variants in cultured neurons
The two rationally generated mutants A56P and TP [22],
the inherited A30P mutation, human WT aSynuclein, and
EGFP were expressed in cultured primary cortical neurons
using AAV2 vectors. The functional titers of the recom-
binant viral vectors were equal, i.e., all vectors express the
same amount of aSynuclein (Fig. 1a). To validate that the
artiﬁcial, oligomeric mutants A56P and TP indeed showed
strongly impaired aggregation, we assessed the generation
of aggregated aSynuclein by probing its resistance against
PK digestion. Protein lysates of transduced neurons were
digested with PK for either 5 or 30 min and the percentage
of PK-resistant aSynuclein was quantiﬁed as a measure of
aggregate formation. All values were normalized to the
respective control levels without digestion. While 18% of
WT aSynuclein and 30% of A30P aSynuclein were resis-
tant to PK-digestion, this fraction decreased to\5% for the
A56P and TP mutants (Fig. 1b, c). This observation cor-
roborates results obtained by earlier in vitro studies
demonstrating that A56P and TP form less aggregates in
solution than WT or A30P [22].
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aSynuclein variants in adult DA neurons
of the rat SNpc
We then assessed the formation of aggregates in midbrain
tissue sections derived from adult rats by quantifying the
amount of PK-resistant aSynuclein. These animals were
injected into the SNpc with AAV vectors expressing WT,
A30P, A56P or TP aSynuclein 4 weeks before tissue sam-
pling. Control rats received identical injections of a AAV
vectorencodingEGFP.Tissuesamplesweresubjectedtothe
maximum possible dose and incubation time of PK, which
was just below the threshold of completely digesting the
tissue specimen. Untreated sections adjacent to the treated
ones served as controls. This method has been shown to be
themostsensitiveproceduretodetectaSynucleinaggregates
in tissue specimen including post-mortem patient’s brain [4,
32]. After immunohistochemistry with the human aSynuc-
lein speciﬁc antibody syn211, PK-resistant aggregates were
identiﬁed as small intensely stained inclusions of about
0.5 lm in diameter in cell bodies of DA neurons. The neu-
ropil of untreated slices showed relatively large, focal bead-
like swellings immunoreactive for aSynuclein. With PK
treatment, we detected smaller proﬁles but with similar
spatial arrangement (Fig. 2a–o). PK-resistant aggregates in
the neuropil were quantiﬁed by calculating the fraction of
aSynuclein-positive material using the ImageJ software.
PK-resistant aggregates in neuronal cell bodies were quan-
tiﬁed by counting of individual aggregates. Without PK
treatment,aSynucleinimmunoreactivity in the neuropil was
equal for all aSynuclein variants 4 weeks post transduction.
FollowingPKtreatment,WTandA30Pexpressingspecimen
demonstrated signiﬁcantly higher levels of aSynuclein
immunoreactivity as compared to A56P and TP (Fig. 2p).
The number of PK-resistant intraneuronal aSynuclein
aggregates was signiﬁcantly higher in WT- and A30P-
expressing neurons (99.1 ± 12 and 53.6 ± 20.6, respec-
tively) compared to A56P- and TP-expressing neurons
(5.9 ± 3.3and3.4 ± 3.8,respectively)(Fig. 2q).ThesePK-
resistant aggregates did not co-stain with ThioS (Fig. 3). No
aggregates were detectable in neurons of undigested sec-
tions, in PK-digested sections after EGFP overexpression or
in the contralateral nigra (not shown). In contrast to the
biochemicalPK-resistanceassayconductedwithcelllysates
from cultured non-DA cortical neurons, we found that
expression of WT aSynuclein in adult rat DA neurons pro-
duced signiﬁcantly more aggregates than expression of
A30P, suggestingthatthe durationofthe expression, theage
of the neurons or the DA environment may differentially
impact on aggregate formation.
To study the time course of aggregate formation in our
in vivo model, we analyzed tissue sections obtained
2 weeks after viral-vector injection. Abnormally accumu-
lated abundant cytoplasmic PK-resistant aggregates had
already developed in nigral neurons overexpressing WT
aSynuclein (Fig. 2r). The detected aggregates had, how-
ever, a smaller individual grain size compared with
aggregates 4 weeks after injection.
As the aggregates were resistant to PK and thus likely
consisted of ﬁbrillar aSynuclein [8, 33], the extensive prior
classiﬁcation of WT and A30P aSynuclein as ﬁbril-forming
variants, and A56P and TP as ﬁbrillization impaired vari-
ants [22] was conﬁrmed in DA neurons of adult rats in vivo.
Only ﬁbril-forming aSynuclein variants induce
a long-lasting progression of DA neuron degeneration
Overexpression of WT, A30P, A56P, TP aSynuclein, and
EGFP in rat nigral neurons was performed by means of an
AAV2 serotype vector. The efﬁcient transduction of all
brains and expression of each construct was conﬁrmed by
immunohistochemistry. Neuronal localization of aSynuc-
lein was studied by double immunoﬂuorescence with the
dopaminergic-speciﬁc marker TH (Fig. 4d–i). Due to the
documented inhibitory effect of aSynuclein on TH
expression [45], all cell counts were performed using
immunohistochemistry for VMAT2 (Fig. 4l).
Survival of DA neurons was ﬁrst analyzed 2 weeks after
vector administration and already showed an extensive loss
of DA neurons in the SNpc of animals expressing the
human WT aSynuclein (43 ± 3%, compared with the non-
injected control side). Only WT aSynuclein caused sig-
niﬁcant neuronal death at this early time point. Two weeks
Fig. 1 Assessment of formation of PK-resistant aggregates in
cultured primary neurons. a Western blot analysis of AAV2-
expressed aSynuclein using total cell lysates from rat primary
cortical neurons 6 days after transduction shows equal expression
levels of all aSynuclein variants. Staining with antibody clone 42,
which reacts with human and rat aSynuclein. b Western blot for
aSynuclein on cell lysates from cortical neurons 6 days after
transduction with AAV containing the different aSynuclein variants.
The lysates were digested with PK for 0, 5, and 30 min. Staining with
human speciﬁc antibody syn211. c Quantitative evaluation of band
intensities of western blot analysis for 30 min PK digest. Formation
of PK-resistant material given in % of undigested aSynuclein variant.
Data given as mean ± SD from four independent experiments.
Asterisk indicates a signiﬁcant difference between groups (p\0.05,
paired t test)
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tissue sections at 4 weeks after transduction: formation of PK-
resistant aSynuclein aggregates in vivo. Staining against human
aSynuclein in the SNpc after PK digestion (?PK) or without
digestion (-PK). Overview in upper panel (a–e) and higher
magniﬁcation of the neuropil in middle panel (f–j). Compared to
WT aSynuclein (g), PK-resistant aggregates were less abundant in the
nigral sections expressing the A30P (h) aSynuclein variant, and
nearly absent for A56P (i) and TP (j). Lower panel (k–o) shows high-
power images from cell somata of neurons, illustrating a dramatically
increased number of small, dense inclusions for WT aSynuclein (l).
Those cytoplasmic aggregates were less abundant in the nigral
neurons expressing the A30P (m) aSynuclein variant, and nearly
absent for A56P (n) and TP (o). Scale bars 15 lm. p Quantiﬁcation of
PK-resistant aSynuclein immunoreactive material in the neuropil of
the SNpc 4 weeks after transduction. The difference between
undigested (-PK) and digested (?PK) sections was highly signiﬁcant
for all aSynuclein variants except for WT (Welch Two Sample t test).
Signiﬁcant differences between PK-digested groups outlined below
the graph (Tukey’s, p\0.001). q Number of PK-resistant, aSynuc-
lein-immunoreactive aggregates per neuron. Signiﬁcant differences
between PK-digested groups outlined below the graph (Tukey’s,
p\0.001). n = 7 for WT, n = 8 for A56P, n = 14 for A30P, n = 5
for TP. Data are presented as mean ± SD (r) Representative images
showing neurons expressing the human WT aSynuclein 2 weeks post
injection. PK-resistant aggregates had already developed. They were
smaller in size and more numerous compared with aggregates
2 weeks later
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niﬁcant neurotoxicity. Four weeks after virus injection, we
found that about 50% of DA neurons had degenerated in
tissue expressing either WT (48 ± 17%), A56P (48 ± 8%)
or TP (50 ± 7%) aSynuclein, while 27 ± 9% of DA
neurons had died after expression of A30P aSynuclein
(Fig. 4m). Thus, the preﬁbrillar aSynuclein mutants A56P
and TP induced a similar extent of neurodegeneration as
compared to WT aSynuclein at this time point. However,
in contrast to results obtained in invertebrate and cellular
models [22], preﬁbrillar aSynuclein did not aggravate DA
neuron degeneration compared to WT aSynuclein.
Eight weeks post transduction, WT, A56P, and TP still
produced a comparable extent of neurodegeneration
(56 ± 19, 54 ± 12, 47 ± 8 and 31 ± 13% of DA neurons
had degenerated through expression of WT, A56P, TP and
A30P aSynuclein, respectively).
A fourth group of animals was analyzed 14 weeks after
vector injections (Fig. 4a–m). In these brains, 69 ± 11% of
DA neurons had degenerated in the WT group, and
39 ± 13% in the A30P group, demonstrating a progressive
neuropathology. However, \50% DA neuron loss was
detected in the A56P (42 ± 10) and TP (46 ± 8) groups
(Fig. 4m), indicating that expression of these aSynuclein
Fig. 3 PK-resistant aggregates of aSynuclein and ThioS-positive
structures represent different entities in adult rat DA neurons. To
further characterize PK-resistant aggregates, digested sections were
immunoﬂuorescently stained with a aSynuclein antibody, followed by
a ThioS stain. We detected abundant ThioS-positive structures in DA
neurons independent from aSynuclein expression, i.e., also in DA
neurons of the contralateral nigra. However, these structures were in
no case immunoreactive for aggregated aSynuclein, although we
exploited several different aSynuclein antibodies (Syn211,
aa121–135 of human aSynuclein; LB509, aa115–122, generated
against Lewy bodies as immunogen; clone 42, aa 91–99 of rat and
human aSynuclein; and 5C2, directed against the NAC domain). The
ﬁgure shows ThioS/aSynuclein (Syn211 antibody, confocal detec-
tion) double staining after PK digestion (10 min, 55C, 10 lg/ml) in
SNpc 4 weeks after virus injection. DA neurons in the SN showed
several small ThioS-positive inclusions (d–f) and many aSynuclein-
positive aggregates (a), however, both structures did not colocalize
(g). As shown before, neurons infected with WT aSynuclein
(a) showed considerably more aSynuclein aggregates than neurons
expressing A56P (b)o rT PaSynuclein (c)
676 Acta Neuropathol (2012) 123:671–683
123variants did not cause further progression of DA neuron
degeneration. Instead, cell loss through expression of A56P
and TP aSynuclein had already reached its maximum and
ﬁnal state at 4 weeks. Toxicity in these models could be
entirely attributed to aSynuclein since EGFP controls
showed only marginal evidence of degeneration 14 weeks
post transduction (5.6 ± 4% cell loss).
To determine whether the reduced number of DA cells
in the SN was attributable to an actual loss of cells rather
than to a downregulation of the cellular markers used, i.e.,
the TH enzyme and the VMAT2 protein, we used an
antibody to the neuron-speciﬁc protein NeuN to label ni-
gral neurons. The NeuN marker revealed a marked loss of
SNpc cells on the AAV-aSynuclein-injected side, con-
ﬁrming that the neurons had indeed degenerated.
Quantiﬁcation of NeuN-positive cells in the SNpc of WT
aSynuclein-injected animals 4 weeks post transduction
revealed a 56% reduction compared to the non-injected
side. Percentages of TH-positive cells among NeuN-posi-
tive cells were approximately 60% on the unlesioned side
and increased on average to 68% on the injected sides,
suggesting also a loss of non-DA neurons.
It should be noted that 14 weeks after application of
AAV2-WT aSynuclein, we detected only few DA cell
bodies which demonstrated immunoreactivity for both, the
DA marker TH and human aSynuclein, while robust
aSynuclein immunoreactivity persisted in the dystrophic
remaining neuritis (Fig. 4j). In contrast, in TP and A56P
expressing brains, many neuronal cell bodies were immu-
noreactive for TH and aSynuclein, suggesting that DA
neurons overexpressing the preﬁbrillar aSynuclein variants
can survive for long periods of time (Fig. 4k).
Fibrillar and preﬁbrillar aSynuclein variants are
secreted from rat primary cortical neurons
aSynuclein is secreted from neurons via exocytosis [26]
and aSynuclein-mediated neuropathology could be trans-
mitted from affected to unaffected neurons [10]. To
investigate whether progressive degeneration of WT and
Fig. 4 Only ﬁbrillar aSynuclein variants induce progressive DA
neuron degeneration in vivo. a–i Representative images illustrating
nigral DA neurodegeneration and signiﬁcant overexpression of
aSynuclein in the injected hemispheres by double staining for TH
(red) and aSynuclein (green). Each column contains rostral-to-caudal
coronal sections taken from the same animal and gives an overview of
the extent of nigral DA neuron loss induced by expression of WT
(d–f)o rT P( g–i) aSynuclein at 14 weeks after AAV injection. Non-
transduced control sections are shown in a–c. Higher magniﬁcation
images (j, k) are optical sections of 1 lm and were generated with an
ApoTome. DA cell bodies which demonstrated immunoreactivity for
both, the DA marker TH and human aSynuclein, were found more
frequently for TP than for WT. (l) Representative image of a coronal
section showing nigral degeneration in a AAV-WT aSynuclein-
injected animal. The nigral DA neurons were speciﬁcally labeled with
an antibody against VMAT2 and with standard DAB immunohisto-
chemistry. The expression of WT aSynuclein led to loss of VMAT2-
positive neurons in the SNpc, compared with the contralateral intact
side. m Changes in total number of VMAT2-positive cells in SNpc
over time, as determined by stereology in the AAV-aSynuclein-WT,
A30P, A56P, TP and AAV-EGFP-injected rats (n = 5–6 animals per
time point and group). Data are shown as mean ± SD; signiﬁcant
differences between groups outlined below the graph (Tukey’s test)
b
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secretion of aSynuclein, we overexpressed the aSynuclein
variants in primary cultured neurons and quantiﬁed the
amount of released aSynuclein in the culture medium. To
collect the secreted proteins, the neurons were cultured in
fresh medium for 48 h. The supernatant was analysed under
denaturing and native conditions (Fig. 5a–e). Secreted
aSynuclein was found to migrate as a single 14 kDa band
under denaturing conditions, and at *60 kDa in gels when
loaded without DTT/b-ME. aSynuclein WT, and all mutant
variants were secreted from neurons. The highest amount
was detected in the conditioned medium of WT-transduced
cultures (n = 5 experiments), suggesting that enhanced
secretion of human WT aSynuclein could contribute to the
progressive degeneration induced by this variant.
The amount of released aSynuclein in the conditioned
medium correlated with the intracellular expression levels
of this protein (Fig. 5f). In the same set of cultures,
endogenously expressed cytosolic protein tubulin was not
detected in the culture medium, indicating that aSynuclein
release was not the result of membrane leakage caused by
cell death. To further corroborate that release of aSynuclein
is not caused by dying neurons, we counted aSynuclein-
positive neurons in primary cultures at 5, 7 and 9 days post
transduction. No substantial decrease in cell number over
time was detected. Since we found no sign of increased cell
death in neurons overexpressing WT aSynuclein, we can
exclude the possibility that the enhanced release of WT
aSynuclein into the culture medium is attributable to
membrane leakage (Fig. 5g).
Fig. 5 Secretion of overexpressed aSynuclein from primary cortical
neurons. Cells were infected with the respective AAV vectors on day
3 in vitro. The conditioned medium and the cell lysates were collected
at day 9 post transduction after 48 h of incubation in fresh medium.
The conditioned medium (a) and the whole-cell extracts (b)o f
transduced cortical neurons were subjected to denaturing gel electro-
phoresis. Non-denaturing gel electrophoresis of aSynuclein from
conditioned medium (c) and of aSynuclein isolated from cell pellet
(d) with protein loading control (e). Molecular weight markers in kDa
indicated on the right. Release of aSynuclein WT was enhanced
compared with the other aSynuclein variants. f Secretion of
aSynuclein correlates with its expression levels. Primary cortical
neurons were transduced with three different titers of AAV-WT
aSynuclein and the levels of intracellular (cell lysate) and released
(medium) proteins were analyzed. Secreted proteins were collected
for 48 h. In contrast to aSynuclein, tubulin was not released from the
cells. g Neurotoxicity of WT and mutants of aSynuclein in rat
primary cortical neurons transduced with AAV. Numbers of aSyn-
uclein-positive neurons counted after transduction with respective
aSynuclein variants. Expression of WT aSynuclein did not result in a
lower number of surviving neurons compared with A30P, A56P and
TP aSynuclein after 5 and 7 days, indicating that enhanced release of
human WT aSynuclein into the medium was not the result of
membrane leakage caused by cell death. Data are shown as
mean ± SD
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123Differential striatal axonal pathology induced
by aSynuclein ﬁbrillar and preﬁbrillar variants
Nigral aSynuclein overexpression resulted in aSynuclein
immunoreactivity in striatal projections of nigral DA
neurons. The measured density of DA projections in
the striatum correlated with the extent of nigral
neurodegeneration, i.e., aSynuclein WT overexpression
induced signiﬁcantly more ﬁber loss as compared to TP
and A30P overexpression (Fig. 6). aSynuclein immunore-
active striatal ﬁbers displayed large numbers of dystrophic
swollen proﬁles, which colocalized with the DA marker
TH and morphologically differed considerably between
WT, TP and A30P aSynuclein-expressing specimen
(Fig. 7). Following WT overexpression, extensive beading
of neuronal processes could be detected (Fig. 7a, d). In
contrast, TP overexpression resulted in the appearance of
large axonal retraction bulb-like structures, while the axon
proximal to the retraction bulb showed fewer varicosities
(Fig. 7b, e). A30P overexpression, which in nigral DA
neurons resulted in fewer PK-resistant aggregates than WT
but more such aggregates than TP, displayed an interme-
diate axonopathy. It induced fewer small, bead-like
varicosities but more large retraction bulb-like proﬁles than
WT aSynuclein (Fig. 7c, f). Thus, it appeared that aggre-
gating aSynuclein WT resulted in extensive beading of
neuronal processes, while less- and non-aggregating
aSynuclein variants demonstrated a preference for gener-
ating large axonal retraction bulb-like structures. These
results suggest that ﬁbrillar and preﬁbrillar variants of
aSynuclein induce different modes of axonopathy in nigral
DA neurons.
Discussion
aSynuclein constitutes the major component of Lewy
bodies and amyloid plaques [34], and its causal contribu-
tion to the etiology of Parkinson’s disease is evident [16].
aSynuclein can adopt several oligomeric and ﬁbrillar
Fig. 6 Loss of TH-positive innervation in the striatum after expres-
sion of a ﬁbrillar aSynuclein variant (WT) or the preﬁbrillar variant
TP. Representative images illustrating the axonal ﬁber innervation in
the striatum 14 weeks after AAV-mediated gene transfer into the SN.
Overview of coronal sections showing transgene expression of EGFP
(a), WT aSynuclein (b), and TP aSynuclein (c). Nigrostriatal ﬁber
terminals in the striatum were ﬁlled with the transgenic protein.
Immunohistochemical staining for TH (d–f) revealed that in contrast
to the AAV-EGFP-injected animals (d), the expression of aSynuclein
led to the appearance of degenerative changes and a loss of striatal
ﬁbers, which was more pronounced for WT (e). Scale bar 500 lm.
g–o Higher magniﬁcation images covering the dorsal, medial and
ventral area of a representative striatal section of an intact non-
transduced control side (g–i), WT-transduced (j–l), and TP-trans-
duced (m–o) brain. TH-immunostained sections showing the extent of
loss of striatal innervation. Remaining ﬁbers in the WT aSynuclein-
treated animals were sparse. Scale bar 100 lm. p Quantiﬁcation of
ﬁber density revealed a clear reduction in TH-positive striatal
innervation in the aSynuclein transduced animals at 14 weeks after
injection (signiﬁcant difference from the EGFP-transduced control
group at p\0.001). The difference between the WT and TP variant
was also signiﬁcant (p = 0.048), whereas the difference between
A30P and TP was not
b
Acta Neuropathol (2012) 123:671–683 679
123conformation states, but it is still uncertain which of the
different conformational states of aSynuclein mediate
neurotoxicity. The present study was motivated by recent
results showing that rationally designed mutants of aSyn-
uclein showed dramatically reduced propensity to form
insoluble aggregates in solution and in C. elegans, and that
these variants of aSynuclein demonstrated enhanced
neurotoxicity in mammalian cell lines, Drosophila, C.
elegans and cultured rat DA neurons [22]. These results
were interpreted as a conﬁrmation of the ‘‘toxic oligomer’’
hypothesis in the sense that the primary toxic species of
aSynuclein are preﬁbrillar, putatively soluble oligomeric
conformations.
Extensive biophysical analysis demonstrated that the
point mutations neither alter the structural properties of the
protein as monomer in solution, nor prohibit the formation
of an a-helical conformation on the surface of SDS
micelles, but strongly differed in their ability to form
amyloid ﬁbrils. All variants efﬁciently bind to phospholipid
vesicles. The vesicle afﬁnity of A56P or TP aSynuclein
was very similar to that observed for A30P [22].
We report on a rat model using AAV2 delivery of
aSynuclein that differs in the rate of progression and
severity in DA pathology based on the variant of AAV2-
aSynuclein injected. Human-WT aSynuclein caused a
rapid onset of nigral pathology (within 2 weeks), including
the abundant presence of PK-resistant aggregates of
aSynuclein, and a continuous progressive loss of DA
neurons between 2 and 14 weeks. Expression of A30P
aSynuclein also caused a gradually progressive loss of DA
neurons, but with a later onset compared to WT. The
preﬁbrillar aSynuclein variants produced initially only
marginal signs of toxicity (at 2 weeks) followed by a
dramatic DA cell death at 4 weeks, however, without fur-
ther progression. Thus, interestingly, the non-aggregating
aSynuclein variants showed clearly different kinetics of
toxicity compared to those aSynuclein variants that are
able to form ﬁbrils (WT and A30P). Taken together, our
results highlight a possible link between ﬁbrillization of
aSynuclein and progressive neurodegeneration. We are
neither suggesting that the propensity of aSynuclein to
aggregate is the only property nor that it is the main
property of the protein causing DA neurodegeneration, but
our results clearly indicate that aggregation plays a major
role in the progression of DA cell loss and that aggrega-
tion-impaired mutants have lost the ability to trigger a
sustained neurodegeneration.
We demonstrate that the preﬁbrillar aSynuclein variants
A56P and TP form fewer PK-resistant aggregates as
compared to WT aSynuclein and the familial A30P
mutation, not only in cultured primary cortical rat neurons
but also in neurites and cell bodies of adult nigral DA
neurons in vivo. Thus, these proteins behaved in vivo as
predicted by biophysical assessments in deﬁned solutions
[22]. However, in contrast to cell culture and invertebrate
models, the preﬁbrillar mutants did not amplify aSynuc-
lein-related degeneration of rat DA neurons in vivo as
compared to the WT protein. Whereas at 4 and 8 weeks
after viral-vector application cell death was still compara-
ble between ﬁbrillar WT aSynuclein and preﬁbrillar
Fig. 7 Distinctive axonal dystrophies detected in striatum after
aSynuclein-WT, A30P or TP expression in nigral DA neurons.
Representative examples of dystrophic axons in the striatum after
expression of WT (a), TP (b) and A30P (c) aSynuclein. Immuno-
histochemistry with anti-aSynuclein antibody 5C2 against the NAC
domain (green). Pictures show overlay with nuclear DAPI stain
(blue). Scale bar 10 lm. Quantiﬁcation of the sizes of TH-positive
axonal swellings detected after aSynuclein-WT (d), TP (e) or A30P
(f) expression. Note that the x axes are truncated and continue in the
inserted histogram with a changed scale for the y axis to depict the
quantiﬁcation of large retraction bulbs as detected predominately after
aSynuclein-TP expression. Quantitative data were extracted with the
NIH MacBiophotonics ImageJ software with the analyze-particles
function. Measurements were performed on one rostral and one
caudal section for each brain. Numbers of counted structures:
aSynuclein-WT, 4,178 objects from n = 5 animals; aSynuclein-TP,
3,837 objects from n = 5 animals; aSynuclein-A30P, 1,856 objects
from n = 4 animals
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123variants, WT was the most toxic variant after 14 weeks of
expression. Among the mutants, A56P and TP caused a
stronger cell loss at 4 and 8 weeks, but they were neither in
the beginning (2 weeks) nor at a later stage (14 weeks)
more toxic than A30P. Thus, already after 4 weeks, the
neurotoxic effect of the preﬁbrillar mutants appeared to
have subsided, because after an initial insult the remaining
neurons survived despite the fact that the level of aSyn-
uclein expression remained high. These results show that
nigral DA neurons were vulnerable to high levels of either
WT or mutant aSynuclein, however, only the ﬁbril-forming
WT and A30P variants of aSynuclein caused a progressive
form of DA neuron degeneration.
Thediscrepancybetweenourcurrentresultsandprevious
workconductedininvertebratemodelsandculturedprimary
neurons [22] with respect to aSynuclein toxicity highlights
the necessity to conﬁrm studies that investigate the neuro-
toxic consequences of aSynuclein aggregation also in adult
mammalian DA neurons in vivo. Given that aSynuclein is a
very abundant protein in mammalian brain [19] it is likely
that mammalian neurons have developed mechanisms to
modulate aSynuclein aggregation, which do not exist in
invertebrate neurons. Furthermore, our current results
demonstrate that even in rat DA neurons, in vivo expression
of oligomeric versus ﬁbril-forming aSynuclein variants can
lead to divergent results. Ina recent study [44], it was shown
that artiﬁcial mutants disrupting salt bridges between b-
strands of aSynuclein (E35K or E57K) generated more
oligomers and less ﬁbrils than WT or A30P aSynuclein in
aggregationassaysunder certain conditions(butmoreﬁbrils
under different conditions), and that these mutants were
signiﬁcantlymoretoxicthanWTorA30PaSynucleinforrat
DA neurons in vivo. Thus, differences in experimental
design with respect to the nature of the aSynuclein muta-
tions (disrupting salt bridges between b-strands through
lysine substitutions [44] versus directly disrupting b-sheets
through proline substitutions [22]), viral-vector system and
promoter, duration of transgene expression, and readout of
aggregate formation in vivo make it difﬁcult to evaluate the
toxic oligomerhypothesis, andwarrantfurther studies under
more matching conditions.
Progressive neurodegeneration and its correlation to the
formation of PK-resistant aggregates were assessed in our
current study for the ﬁrst time. The composition of PK-
resistant aSynuclein aggregates is incompletely deﬁned but
ample evidence suggests that they consist at least partially
of ﬁbrillar aSynuclein. aSynuclein ﬁbrils generated in vitro
[8, 14, 30, 33], and ﬁbrillar aSynuclein in the detergent-
insoluble fraction of human synucleinopathy brains are
resistant to PK digestion [30, 33]. In contrast, small-sized
oligomers are not PK-resistant as recently shown in brain
lysates of A53T transgenic mice [40]. Colocalization of
aSynuclein aggregates with the classical amyloid stain
ThioS has been reported [2] but it was absent in many other
studies [21, 24, 25, 31]. Such colocalization may crucially
depend on the accessibility of exposed grooves, which are
rich in aromatic residues, on the surface of amyloid ﬁbrils
[5]. Despite the missing colocalization with ThioS, the
resistance of aggregates of WT or A30P aSynuclein to PK
is in agreement with a very stable structure as found in
amyloid ﬁbrils.
We report here that ﬁbrillar and preﬁbrillar aSynuclein
variants caused divergent axonal pathologies, further
exemplifying that they induce neurotoxicity by different
means. Degenerating axons of WT aSynuclein expressing
DA neurons displayed a multitude of small varicosities of
about 30–50 lm
2 area, but very few large retraction bulb-
like proﬁles larger than 300 lm
2 in size. Conversely, axons
of TP aSynuclein-expressing DA neurons demonstrated
fewer small varicosities but more large retraction bulb-like
proﬁles. Thus, axonal transport and/or structural integrity
appear to be differentially affected by the presence of
aSynuclein variants which are impaired in ﬁbrillation
(A56P/TP) as compared to those variants which have high
propensity to form ﬁbrils (WT/A30P).
In our rodent model, the familial A30P mutant was found
to be less toxic than human WT aSynuclein at all investi-
gated time points. This is in agreement with another rat
model using rAAV2/6-mediated expression of aSynuclein
in which WT aSynuclein displayed stronger toxicity than
the A30P mutant when assayed 8 weeks post-virus injection
[2]. Even though WT and A30P are both ﬁbrillar aSynuc-
lein variants, we provided evidence that A30P is less likely
to aggregate in vivo, which is in agreement with many other
studies showing that A30P does form ﬁbrils, but ﬁbrillizes
more slowly than WT [9, 28]. This could explain, at least in
part, the differences in toxicity between these aSynuclein
variants, but is most likely not the only reason. The A30P
mutation reduces the afﬁnity of aSynuclein for biological
membranes and this may have an impact on pathophysio-
logical effects [1]. Indeed, it has been shown that the A30P
mutant fails to impair the growth of yeast cells [35].
Our models demonstrate that aSynuclein overexpression
for 4 weeks is sufﬁcient to trigger signiﬁcant nigral DA cell
loss independent of the aSynuclein species. Two weeks
after transduction, both the ﬁbrillar as well as preﬁbrillar
proline mutants showed only marginal evidence of degen-
eration. After 4 and 8 weeks of overexpression, A56P and
TP displayed higher toxicity than the A30P mutation. This
could be taken as an argument for the toxic oligomer.
Nevertheless, at 14 weeks post transduction, the A30P
mutant had already reached the same toxic effect as A56P
and TP. Those aSynuclein species that have the potential to
trigger a gradual progression of neurodegeneration are
likely to be the most toxic at long term, even if they do not
cause the highest cell loss at intermediate time points. It was
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123reported that A30P induced a time-dependent degeneration
process and that at 5 months expression, A30P had caused
the same loss of TH-positive nigral neurons as WT aSyn-
uclein [29]. Another study also detected no signiﬁcant
difference in loss of TH-positive neurons between WT and
A30P [44]. Likewise, a study in mice did not ﬁnd any
obvious difference in pathogenicity between the WT and
A30P mutant form of aSynuclein [25] implying that A30P
can induce the same extend of neuronal loss as WT.
We hypothesize that the ability of aSynuclein to form
ﬁbrils is required for progressive neurodegeneration. The
A53T variant of aSynuclein has an increased aggregation
propensity in vitro and forms ﬁbrils more quickly than
human WT aSynuclein [28]. The ﬁnding that AAV-medi-
ated overexpression of mutant A53T aSynuclein results in
progressive, time-dependent DA neuron loss in rats is
consistent with our idea. In animals given either WT or
A53T aSynuclein, the pathological changes were similar,
both quantitatively and qualitatively [23] and the authors
noted a similar appearance of aSynuclein-positive cyto-
plasmic inclusions and granular deposits as described in the
present study. In a different report, overexpression of A53T
aSynuclein in the rat nigra resulted in protracted, but
nevertheless progressive neurodegeneration [7]. The
delayed degeneration may be related to the fact that human
A53T corresponds to WT aSynuclein in rodents. The
demonstrated gradual loss of DA cell bodies in the SN
caused by the ﬁbrillar mutant A53T is in agreement with
our conclusion, that aSynuclein ﬁbril formation is not an
epiphenomenon but mechanistically involved in progres-
sive neurodegeneration.
In conclusion, generation of both soluble oligomers and
PK-resistant aggregates of aSynuclein leads to death of
mammalian DA neurons in vivo, but formation of PK-
resistant aggregates is required for the induction of pro-
gressive degeneration of DA neurons as found in PD
patients. The formation of PK-resistant ﬁbrillar aggregates
may thus represent the critical pathomechanism that needs
to be targeted to achieve a slowing down of the progression
of PD and related synucleinopathies.
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